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Background: The management of asymptomatic pancreatic cysts is controversial and indications for
excision are based on pathology and natural history.
Objectives: This study aimed to examine outcomes of asymptomatic lesions using a protocol based on
size and cyst fluid analysis.
Methods: Asymptomatic cysts were identified from a prospectively maintained database. Sequential
cross-sectional imaging studies were assessed, and results of endoscopic ultrasound-guided aspiration
were co-analysed.
Results: A total of 338 asymptomatic patients underwent evaluation. Overall, 84 cysts were <1.5 cm and
254 were 1.5 cm in diameter. Median patient follow-up was 5.1 years [interquartile range (IQR): 4.1–6.9
years]. In the group in which cysts measured <1.5 cm in diameter, median cyst size was 1.0 cm (IQR:
0.6–1.2 cm) at presentation and increased to 1.2 cm (IQR: 0.7–1.6 cm) during follow-up. Five (6.0%)
patients underwent resection, all within 2 months of presentation. In the group in which cysts measured
1.5 cm in diameter, median cyst size was 2.5 cm (IQR: 2.0–3.4 cm) at presentation and increased to
2.7 cm (IQR: 3.0–4.2 cm). A total of 63 (24.8%) patients underwent resection. Surgery was performed with
2 months in 53 (84.1%) patients, within 12 months in four (6.3%) patients and at >12 months post-
presentation in six (9.5%) patients. A total of 70.6% of resected specimens were identified as malignan-
cies or mucinous lesions.
Conclusions: Asymptomatic cysts of <1.5 cm in diameter can safely be followed by imaging and are
expected to undergo little change. A quarter of all asymptomatic cysts measuring 1.5 cm are appro-
priately resected based on imaging and cyst fluid analysis.
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Introduction
The widespread use of cross-sectional imaging has led to the more
frequent identification of asymptomatic pancreatic cystic disease
and reported prevalences increase with each incremental
improvement in technology.1–4 In a population of 24 039 patients
undergoing computed tomography (CT) or magnetic resonance
imaging (MRI) during the period 1995–2002, Spinelli and col-
leagues identified pancreatic cysts in 1.2% of patients, although
0.7% of the sample had no history of pancreatitis.1 Subsequently,
Laffan et al. reported a prevalence of 2.6% using multi-detector
CT2 and Lee et al. identified cysts in 13.5% of their cohort using
MRI.3 Most recently, Girometti et al. reported the prevalence of
pancreatic cysts to be 44.7% in patients undergoing magnetic
resonance cholangiopancreatography (MRCP) for non-pancreatic
indications.4
The management of asymptomatic pancreatic cystic neoplasms
remains controversial. The original approach to the management
of cystic lesions in many centres was to offer resection for all
mucinous lesions; however, better understanding of these lesions5
means that the need for excision is now usually based on the likely
pathology and natural history of the lesions identified. It is impor-
tant that the type of cyst present is identified accurately at an early
stage as the spectrum of histopathological possibilities is wide and
includes some entities that require resection and others that can
be safely observed.
This manuscript was presented at the annual AHPBA meeting, Miami, 7–11
March 2012 and at the 10th World IHPBA Congress, Paris 1–5 July 2012.
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There is no doubt that patients with intraductal papillary muci-
nous neoplasms (IPMNs) involving the main duct (MD-IPMN)
require resection,6 as do those with mucinous cystic neoplasms
(MCNs)7 in view of the risk for malignant transformation. The
optimal management of IPMNs arising from side branches (SB-
IPMN) of the main pancreatic duct is less clear as their natural
history and malignant potential are less well defined than those of
the main duct variant.8 However, as a recent study suggests a 20%
incidence of malignancy at 10 years, it is clear that they require at
least careful observation.9
It is apparent that cyst size alone is an inadequate factor with
which to differentiate cyst types and need for resection.10 Most
centres have now developed pathways for the characterization of
asymptomatic lesions based on a combination of cross-sectional
imaging, endoscopic ultrasound (EUS) and cyst aspiration, and
have consequently developed a selective resection policy.11–22
The present group has previously studied the natural history of
indeterminate pancreatic cystic neoplasms5 and devised an inves-
tigation and management protocol based on size and cyst fluid
analysis.23 The aims of this study were to examine the protocol in
a larger series of asymptomatic patients and to confirm its validity.
Materials and methods
Details of all patients with pancreatic cysts managed by the mul-
tidisciplinary pancreas team are held in an institutional prospec-
tively maintained database, established in 1999 following approval
by this institution’s review board. Patients were initially evaluated
within either the Hepatopancreatobiliary Section of the Depart-
ment of Surgery, or the Therapeutic Endoscopy Section of the
Department of Gastroenterology. The pancreatic surgeons and a
pancreatologist conduct a joint clinic which allows any patients
in whom cystic lesions are identified in the morning clinic to
undergo EUS in the afternoon. Patients for whom management
decisions are complex are presented at a weekly hepatopancreato-
biliary case conference attended by surgeons, gastroenterologists,
radiologists and pathologists.
Data were collected prospectively using a standardized elec-
tronic data form that required conclusions on the aetiology of
symptoms. Patients with vague or non-specific symptoms were
considered asymptomatic, although they had originally prompted
the imaging study that led to the discovery of the cyst. The data-
base was interrogated to identify all patients who presented with
asymptomatic pancreatic cysts from January 2000 to July 2009.
Demographic details collected included data on age, gender and
cyst size. Patients were managed according to the algorithm used
in this centre, which has been published previously24 and is illus-
trated in Fig. 1. In brief, cross-sectional imaging studies were
assessed and EUS-guided fine needle aspiration (EUS FNA)
[sequentially: cytology +mucin, carcinoembryonic antigen (CEA)
and amylase] was performed in patients with cysts measuring
1.5 cm. The size selected for routine aspiration was based on
data published by the present group which correlated cyst size and
location with ability to obtain a complete aspiration results pro-
file.23 Endoscopic US and aspiration were also employed intermit-
tently on cysts irrespective of size, based on referral pattern. The
cut-off level of CEA for the diagnosis of a mucinous lesion was
192 ng/ml as per the International Consensus guidelines.8
Patients presumed to have a diagnosis of MD-IPMN or MCN
were advised to undergo resection, as were those with suspicious
radiological features (cysts with associated mass, mural nodules,
duct obstructions, cyst rim calcifications) or cytological atypia on
cyst aspiration. The presence of mucin and the CEA were also
considered in the diagnostic process, principally to diagnoseMCN
and SB-IPMN.
Individuals within the surveillance programme underwent
sequential imaging studies. Subjects who developed radiological
features suspicious for malignancy and those who became symp-
tomatic during observation underwent secondary resection. In
patients in whom cysts measured 1.5 cm in diameter, imaging
was performed at 6-month intervals initially in order to obtain a
perspective on cyst growth rates. If there was no significant growth
during the first year, the interval was increased to 12 months. In
patients in whom lesion diameter measured <1.5 cm, scans were
performed at 12-month intervals. The choice of imaging modality
(CT or MRI) depended on which modality best demonstrated the
lesion at baseline. Repeat aspiration was performed for an increase
in cyst size if the patient remained asymptomatic.
Indications for surgery and the findings of histopathological
examination, including degree of dysplasia, were recorded for all
patients undergoing surgery.
Data were expressed as the median and interquartile range
(IQR).
Results
During the period January 2000 to July 2009, 540 patients were
registered in the database and 338 (62.6%) of these were asymp-
tomatic. The group included 228 women and 110 men with a
median age of 67 years (IQR: 57–75 years). The median length of
follow-up from the time of registration was 5.1 years (IQR: 4.1–
6.9 years).
The median cyst size at presentation was 2.0 cm (IQR: 1.4–
3.0 cm) and the maximal size was 15.0 cm. The cysts were divided
into lesions measuring <1.5 cm and those measuring 1.5 cm in
diameter for the purposes of further investigation. The rationale
for choosing this cyst diameter for stratification is based on find-
ings in prior studies that demonstrated that a diameter of 1.5 cm
is required for successful EUS FNA as smaller diameters provide
inadequate aspirate volumes for characterization.24 At registra-
tion, 84 cysts were found to measure <1.5 cm and 254 to measure
1.5 cm in diameter.
Cysts of <1.5 cm in diameter
In the group in which cysts measured <1.5 cm in diameter, the
median cyst size at presentation was 1.0 cm (IQR: 0.6–1.2 cm). In
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four of the patients with lesions measuring <1.5 cm, mural
nodules were identified on cross-sectional imaging; these patients
underwent US-guided cyst aspiration. The fifth patient had a past
medical history positive for renal cell carcinoma and was found to
have a cystic lesion identified on routine follow-up imaging. The
following patterns were seen in the four patients with suspicious
imaging who underwent EUS: mucin and cellular atypia (n = 1);
mucin and raised CEA (n = 1); mucin and mural nodule (n = 1),
and mucin alone (n = 1).
Five (6.0%) patients in this group underwent resection, all
within 2 months of initial presentation. Indications for surgery
were suspicious findings during cyst evaluation (Table 1). The
operations performed included four distal pancreatectomies and
one pancreatoduodenectomy.
Histopathological findings are summarized in Table 2. Histo-
pathology confirmed the lesions with a mural nodule and atypia
MRI with secretin
Symptomatic or suspicious imaging
(nodule/main duct IPMN) Asymptomatic
≥ 1.5 cm < 1.5 cm
EUS cyst aspiration
 CEA, cytology, mucin, amylase
Atypia All negative(SCN)
Interval review and scanning
Resection
Size increase
EUS aspiration
Symptoms
Suspicious imaging
Mucin/CEA
No amylase
(MCN) 
Mucin/CEA
+/– amylase
(SB-IPMN)
Figure 1 Algorithm for the management of pancreatic cystic neoplasia. MRI, magnetic resonance imaging; IPMN, intraductal papillary
mucinous neoplasm; EUS, endoscopic ultrasound; CEA, carcinoembryonic antigen; MCN, mucinous cystic neoplasm; SB-IPMN, side-
branch IPMN
Table 1 Indications for primary and secondary operations under-
taken in patients with asymptomatic pancreatic cysts
Indications for surgery Cyst
diameter:
<1.5 cm
(n = 5)
Cyst
diameter:
1.5 cm
(n = 63)
Operations performed after initial
presentation and investigation, n
Based on imaging protocol 5 53
Operations performed during surveillance, n
Based on development of symptoms 0 2
Based on development of new features
on imaging
0 6
Based on patient choice 0 2
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to be SB-IPMNs, and the lesion in the patient with a history of
renal carcinoma as a cystic renal metastasis. The patient in whom
a positive staining for mucin emerged in conjunction with a raised
CEA had a histological diagnosis of pseudocyst despite no clinical
history suggestive of acute pancreatitis. The individual with iso-
lated mucin staining was given a final histopathological diagnosis
of a foregut cyst.
During the period of follow-up, the median cyst size increased
from 1.0 cm (IQR: 0.6–1.2 cm) to 1.2 cm (IQR: 0.7–1.6 cm). No
patient in the surveillance programme developed suspicious
radiological findings and none of the patients became symptom-
atic. Furthermore, no additional operative procedures were
performed.
Cysts of 1.5 cm in diameter
In the group inwhich cystsmeasured1.5 cm, themedian cyst size
at presentationwas 2.5 cm(IQR:2.0–3.4 cm).A total of 53 (20.9%)
patients underwent resection following multimodal assessment as
per the protocol (Table 1); 48 of these patients underwent EUS and
aspiration and the remaining five progressed directly to resection
as a result of suspicious radiological findings. The median size of
cysts in patients who underwent resection following the initial
investigation was 2.9 cm (range: 1.5–15.0 cm).
During the follow-up of patients within the surveillance pro-
gramme, the median cyst size increased to 2.7 cm (IQR: 3.0–
4.2 cm). Within this cohort, a further 10 (3.9%) resections were
performed in response to: the development of new radiological
findings (n = 6); the development of symptoms (n = 2), and
patient choice (n = 2). Four (6.3%) patients were operated within
12 months and six (9.6%) at12 months post-presentation. The
median size of cysts in patients who underwent resection follow-
ing surveillance was 3.9 cm (range: 2.6–8.0 cm).
The two most common procedures were left pancreatectomy
(n = 41) and pancreatoduodenectomy (n = 13). Total pancreatec-
tomies were performed in three patients with MD-IPMN.
Parenchyma-sparing resections were performed in six patients and
included central pancreatectomy (n = 3), enucleation (n = 2) and
uncinate resection (n= 1).Therewere no perioperativemortalities.
Histopathological findings in patients who underwent resec-
tion are summarized in Table 2. Of the 63 patients in whom cysts
measured 1.5 cm, 19 had MCNs and eight had IPMNs with
main duct involvement. This group also included two patients
with mucinous adenocarcinomas and four with neuroendocrine
carcinomas. The remaining lesions consisted of 12 SB-IPMNs and
18 benign lesions. Of the patients with SB-IPMNs, the indications
for surgery were radiology and mucin (n = 5), radiology and
raised CEA (n = 5), and radiology and atypical cytology (n = 2).Of
those with a final histological diagnosis of serous cystic neoplasm
(SCN, n = 14), the indications for surgery were: oligocystic lesion
(n = 5), mucin on aspiration (n = 4), elevated cyst CEA (n = 1),
elevated CEA and atypical cells (n = 1), large size (10 cm) (n = 1),
and development of symptoms (n = 3). In the remaining four
benign lesions, indications for resection were atypical cells (n = 2),
radiology and mucin (n = 1), and size (n = 1; 6.0 cm).
In patients who underwent resection after a period of surveil-
lance, histopathological findings in those who submitted to
surgery within 1 year were MCN (n = 2), cystic neuroendocrine
tumour (n = 1) and SCN (n = 1). Both MCNs had developed
suspicious radiological features and the neuroendocrine tumour
had increased in size. Of the six patients who underwent resection
after 1 year, three underwent operations within 2 years and three
were operated at a later time. Final histopathological findings in
the patients who underwent surgery after 2 years of surveillance
were all benign (SCN, n = 2; pseudocyst, n = 1) and surgery was
indicated by the development of symptoms related to the cysts. Of
the patients who underwent surgery within 2 years of presenta-
tion, one patient with a probable MCN developed new radiologi-
cal features, and the other two, both of whom had suspected
SB-IPMNs, requested surgery. Histopathology confirmed the
findings and identified high-grade dysplasia in one of the patients
with SB-IPMN.
Malignant and pre-malignant lesions
Overall, 68 (20.1%) of resections were performed in patients with
initially asymptomatic cysts and 73.5% of these resection speci-
mens revealed either malignant lesions or mucinous cystic lesions
with malignant potential. Importantly, three of the MD-IPMNs
and one of the SB-IPMNs revealed undiagnosed carcinomas
Table 2 Final histopathological diagnoses based on examination of
resection specimens
Histopathology Cyst
diameter:
<1.5 cm
(n = 5)
Cyst
diameter:
1.5 cm
(n = 63)
Mucinous cystic neoplasm, n 0 19
IPMN, n 2 16
Main 0 3
Side branch 2 11
Mixed-type 0 2
IPMN carcinoma, n 0 4
Main 0 3
Side branch 0 1
Mixed-type 0 0
Serous cystadenoma, n 1 14
Chronic pseudocyst, n 1 1
Neuroendocrine carcinoma, n 0 4
Mucinous adenocarcinoma, n 0 2
Ciliated foregut cyst, n 0 1
Developmental cyst, n 0 1
Lymphoepithelial cyst, n 0 1
Renal carcinoma metastasis, n 1 0
IPMN, intraductal papillary mucinous neoplasm.
178 HPB
HPB 2013, 15, 175–181 © 2012 International Hepato-Pancreato-Biliary Association
within the resection specimens. Only one of these had atypical
cells on EUS FNA.
All of the three patients with MD-IPMN but without invasive
carcinoma had evidence of dysplasia (high-grade, n = 1;moderate,
n = 1; low-grade, n = 1). Similarly, both specimens of mixed-type
IPMN showed dysplastic changes (high-grade, n = 1; low-grade,
n = 1). In patients whose resection specimens showed SB-IPMN,
the degree of dysplasia was unspecified in only three cases, and
the remainder showed high-grade (n = 3), moderate (n = 2) or
low-grade (n = 5) dysplastic changes within the cystic lesion.
In addition to the more common mucinous cystic lesions, two
cases of mucinous adenocarcinoma with cystic change, four cases
of neuroendocrine tumours with cystic change, and one renal cell
carcinoma metastasis in a patient in whom resection was the
appropriate treatment were identified.
Serous cystic neoplasms
In 15 patients, the final histopathological diagnosis was SCNs; 12
of these patients underwent primary resection and three devel-
oped symptoms during surveillance and underwent a subsequent
operation. Of those undergoing primary resection following pro-
tocol evaluation, the indications for surgery were: appearance
of a single cyst on imaging without any features to suggest SCN
(n = 5); presence of mucin suggesting MCN (n = 4); elevated CEA
(n = 1); oligocystic lesion with elevated CEA and atypical cells
(n = 1), and large size (10.0 cm; n = 1).
Discussion
The primary finding of this study is that asymptomatic cysts are
common: they were identified in 62.6% of patients in the pancre-
atic cyst database used in this study. This figure is comparable with
the 71% reported by Ferrone et al. in a series of 401 patients15 and
identical to the 62% reported by Gaujoux and colleagues in a
review of 1424 patients treated at the Memorial Sloan–Kettering
Cancer Center over a 15-year period.22 One strength of the current
study’s use of a prospective cohort is that it enables the accurate
documentation of symptoms or the absence of symptoms for each
cyst, something that is inaccurate in retrospective series. Thus, the
present data provide a true reflection of the proportion of asymp-
tomatic cysts referred for evaluation.
It is difficult to be certain of the prevalence of asymptomatic
pancreatic cysts in the general population. There has certainly
been a steady increase in prevalence as cross-sectional imaging has
improved1–4 and the latest technology suggests up to 44.7% of
individuals may have small cysts.4 Indeed, this is almost twice as
high as the 24.3% reported in an autopsy series of 300 cadavers by
Kimura et al.25
It is also clear from multiple centres that the increasing preva-
lence of cyst detection is associated with decreasing lesion size
as a consequence of increases in awareness and the sensitivity
of imaging.12,15,19,22 This only increases the clinical challenges
involved in determining which patients require resection. Ferrone
et al. compared data for the periods 1997–2002 and 2004–2007,
respectively, and noted that the proportion of asymptomatic
patients investigated increased from 36% to 71%, and, corre-
spondingly, the proportion undergoing surgery decreased from
80% to 50%.15 In the present authors’ experience, the median size
of lesions sent for evaluation has halved from 4.0 cm to 2.0 cm
over the last 5-year period.5 Ferrone et al. reported a similar
reduction in the size of lesions referred from 3.3 cm to 2.7 cm.15
In the present study, 20.1% of asymptomatic patients under-
went resection, which is less than the proportions reported by
other authors such as Correa-Gallego and colleagues who reported
that 41% of asymptomatic patients underwent initial resection,
with a further 13% undergoing surgery following a period of
observation.19 However, no-one developed cancer during this
follow-up period, which is the longest in the literature. This sug-
gests that contrary to the perception that an aggressive surgical
approach should be applied in all patients with asymptomatic
cystic pancreatic neoplasms, the vast majority of patients can be
followed safely using the protocol suggested here. Ferrone and
colleagues reported that 50% of their asymptomatic patients
underwent surgery following initial investigation and that a
further 8% did so after follow-up.15 Many surgeons may have a
lower threshold for operating on SB-IPMN lesions andMCNs, but
this may be to the patients’ detriment if they are asymptomatic.
There is little doubt within the pancreatic community that not
all asymptomatic cystic lesions require resection and that a
blanket policy of resection would be neither appropriate based on
the indolent behaviour of many of these cysts nor, indeed, cost-
effective.26,27 The present authors believe that current manage-
ment should be guided by EUS and aspiration with the
development of management protocols.
Centres that deal with large numbers of cystic lesions have
developed protocols for their management. However, there is no
uniform agreement in relation to the cut-off size for investigation
and, particularly, EUS-guided aspiration.12–22 The algorithm used
in Cleveland has a cut-off of 1.5 cm, below which EUS and aspi-
ration are rarely performed. This size was chosen based on the
likelihood that it would allow adequate fluid for analysis.24
However, others use a threshold of 2.0 cm,19,22 and some authors
do not quote specific size criteria for the performance of second-
line investigations.13,17,18 A few centres advocate EUS in all patients
with asymptomatic cysts.16,20
The interval for surveillance represents another factor on which
there is no clear agreement, although many centres21 have adopted
guidelines based on those suggested by Allen and colleagues.12 The
Sendai consensus guidelines recommended annual follow-up for
lesions measuring <1.0 cm, follow-up at intervals of 6–12 months
for cystsmeasuring 1.0–2.0 cm in diameter, and follow-up at inter-
vals of 3–6 months for larger lesions.6 These guidelines were
designed in relation to the surveillance of mucinous tumours
rather than asymptomatic cysts and so their applicability is uncer-
tain. Das et al. applied interval surveillance to 166 cysts believed to
be mucinous neoplasms (117 MCNs and 49 SB-IPMNs).14 Over a
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median follow-up of 32 months, only 11% of these cysts were
found to have grown andmultivariate analysis showed that predic-
tors of significant growth included the initial size of the cystic lesion
and the presence of a mural nodule.14 The authors noted that none
of the cysts exhibited significant growth before 12 months. As a
result, they concluded that a surveillance interval of 2 years would
be adequate.14 However, had such a policy been adopted in the
current series, surgery would have been delayed in four patients
with potentially malignant lesions who underwent resection.
One area of contention refers to the management of SB-IPMN.
The risk for malignant transformation within this tumour is not
well defined: the existing literature suggests rates of between 6%
and 46%.6,15,22,28–33 Most authors suggest a figure at the lower end
of the scale and some suggest even lower rates as the current data
are based on the findings of resection specimens. Indeed, Tanaka
et al. suggested an incidence of 0–5% in asymptomatic
SB-IPMNs.6 The current guidelines suggest that these lesions
should be subject to surveillance and that resection is indicated in
mural nodules, a dilated main pancreatic duct or the development
of symptoms.6,34 Tanno et al. reported that only 11% of SB-IPMNs
showed progressive changes and most of those without nodules
remained unchanged over longterm follow-up.32 The Indiana
University group has also developed management protocols for
pancreatic cystic lesions with the view to identifying those with
high risk for malignant transformation.35,36
In the current study, one of the patients with SB-IPMN had an
invasive carcinoma and three showed evidence of high-grade dys-
plasia; however, cytology was contributory in only one patient
with dysplasia. These data are consistent with those from other
series which claim that accurate prediction of carcinoma and
high-grade dysplasia within SB-IPMNs is difficult to achieve.9,19,39
Furthermore, it may not be possible to accurately determine the
nature of a mucinous lesion preoperatively. Correa-Gallego et al.
reported that this histological diagnosis was confirmed in only
64% of 50 patients undergoing resection of presumed SB-IPMN,
and that 20% showed mixed-type IPMN with histological evi-
dence of main duct involvement.19 Another interesting aspect to
this controversy concerns the patient’s perspective. If a patient
with an SB-IPMN is told that he or she has a 20% risk for cancer
at 10 years, as recently suggested,9 that no test is able to categori-
cally indicate that the patient does not have cancer at presentation,
and that the development of cancer is associated with reduced
survival, it is not unreasonable to expect that many individuals
will consider this 20% risk to be high and will opt for surgery, as
did two patients in the current series. While accurate data are
lacking, it is important that patients are fully informed of the risks
and benefits of surveillance over resection and, furthermore, that
attempts are made to gather more data on the natural history of
this disease. The national risk for mortality in the USA is in the
order of 3%37 and has fallen to <1% in large-volume centres.38
However, morbidity rates – currently in the order of 50%37 – are
clearly important in asymptomatic patients and must be taken
into account when considering resection. Therefore, at present, as
the natural history of SB-IPMN is unclear, a conservative
approach would appear reasonable.39
One surprising finding to emerge from the present study refers
to the difficulty of diagnosing SCN preoperatively. Only one of the
cysts examined here had the typical features of a SCN: this was a
10-cm lesion. Of the remainder, five were oligocystic lesions of
uncertain aetiology, and the others stained positive for mucin, had
an elevated CEA or had atypical cells on aspiration cytology.
Although such features are unusual for SCNs, these diagnostic
dilemmas have been highlighted previously40 and all series of
asymptomatic pancreatic cysts will include SCNs among the
lesions excised.
Conclusions
Asymptomatic cysts represent a common and important diagnos-
tic dilemma, which, when identified, should be referred to a unit
experienced in the management of pancreatic disease for evalua-
tion and accurate characterization. This should include EUS aspi-
ration for cysts of 1.5 cm in diameter. Lesions suspicious for
malignancy and those believed to have a high malignant potential
should be resected. Lesions with a low malignant potential should
be subjected to clinical follow-up and imaging studies. In the
present series, little change occurred in cyst size in lesions mea-
suring <1.5 cm at presentation. However, an additional 20% of
resections were performed for pancreatic cystic lesions measuring
1.5 cm at presentation in response to increases in size. Estab-
lishing a protocol for asymptomatic cysts based on aspiration
results and imaging is more important than using size as a crite-
rion on which to base management decisions and can avoid
unnecessary resections.
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